title: Accelerated approval and oncology drug development timelines.
authors.forename: Michael L
authors.initials: ML
authors.lastname: Lanthier
authors.forename: Rajeshwari
authors.initials: R
authors.lastname: Sridhara
authors.forename: John R
authors.initials: JR
authors.lastname: Johnson
authors.forename: Ann
authors.initials: A
authors.lastname: Farrell
authors.forename: Patricia
authors.initials: P
authors.lastname: Keegan
authors.forename: Robert
authors.initials: R
authors.lastname: Justice
authors.forename: Richard
authors.initials: R
authors.lastname: Pazdur
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000331:legislation & jurisprudence; D017277:Drug Approval / Q000331:legislation & jurisprudence; D023381:Endpoint Determination; D033161:Government Regulation; D006801:Humans; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence
chemical_list: D000970:Antineoplastic Agents